Study: NCT01353404

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sequence 1
Description: fenofibrate 65mg, fed condition, per oral → fenofibrate 65mg, fasting condition, per oral → fenofibrate 160mg, fed condition, per oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequence 1
Description: fenofibrate 65mg, fed condition, per oral → fenofibrate 65mg, fasting condition, per oral → fenofibrate 160mg, fed condition, per oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequence 1
Description: fenofibrate 65mg, fed condition, per oral → fenofibrate 65mg, fasting condition, per oral → fenofibrate 160mg, fed condition, per oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sequence 2
Description: fenofibrate 65mg, fed condition, per oral → fenofibrate 160mg, fed condition, per oral → fenofibrate 65mg, fasting condition, per oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequence 2
Description: fenofibrate 65mg, fed condition, per oral → fenofibrate 160mg, fed condition, per oral → fenofibrate 65mg, fasting condition, per oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequence 2
Description: fenofibrate 65mg, fed condition, per oral → fenofibrate 160mg, fed condition, per oral → fenofibrate 65mg, fasting condition, per oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Seqeunce 3
Description: fenofibrate 65mg, fasting condition, per oral → fenofibrate 160mg, fed condition, per oral → fenofibrate 65mg, fed condition, per oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seqeunce 3
Description: fenofibrate 65mg, fasting condition, per oral → fenofibrate 160mg, fed condition, per oral → fenofibrate 65mg, fed condition, per oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seqeunce 3
Description: fenofibrate 65mg, fasting condition, per oral → fenofibrate 160mg, fed condition, per oral → fenofibrate 65mg, fed condition, per oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sequence 4
Description: fenofibrate 65mg, fasting condition, per oral → fenofibrate 65mg, fed condition, per oral → fenofibrate 160mg, fed condition, per oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequence 4
Description: fenofibrate 65mg, fasting condition, per oral → fenofibrate 65mg, fed condition, per oral → fenofibrate 160mg, fed condition, per oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequence 4
Description: fenofibrate 65mg, fasting condition, per oral → fenofibrate 65mg, fed condition, per oral → fenofibrate 160mg, fed condition, per oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sequence 5
Description: fenofibrate 160mg, fed condition, per oral → fenofibrate 65mg, fed condition, per oral → fenofibrate 65mg, fasting condition, per oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequence 5
Description: fenofibrate 160mg, fed condition, per oral → fenofibrate 65mg, fed condition, per oral → fenofibrate 65mg, fasting condition, per oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequence 5
Description: fenofibrate 160mg, fed condition, per oral → fenofibrate 65mg, fed condition, per oral → fenofibrate 65mg, fasting condition, per oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sequence 6
Description: fenofibrate 160mg, fed condition, per oral → fenofibrate 65mg, fasting condition, per oral → fenofibrate 65mg, fed condition, per oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequence 6
Description: fenofibrate 160mg, fed condition, per oral → fenofibrate 65mg, fasting condition, per oral → fenofibrate 65mg, fed condition, per oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequence 6
Description: fenofibrate 160mg, fed condition, per oral → fenofibrate 65mg, fasting condition, per oral → fenofibrate 65mg, fed condition, per oral